This assay is designed to sequence the full coding sequence (or nearly full coding sequence) of 53 clinically relevant genes that are commonly mutated in a variety of hematopoietic neoplasms (mainly acute myeloid leukemia and myelodysplastic and myeloproliferative syndromes) for the purpose of identifying somatic mutations (substitutions and insertions/deletions). Mutations with known clinical significance and/or those deemed to be pathogenically related to the biology of each patient’s tumor are reported, and this personalized mutational profile may be useful for prediction of prognosis or response to targeted therapies.

For more details and ordering, please click here.